These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20065267)

  • 21. Trends and patterns of five antihypertensive drug classes between 2007 and 2012 in China using hospital prescription data.
    Xu H; He Y; Xu L; Yan X; Dai H
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):430-7. PubMed ID: 25828638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers.
    Meka N; Katragadda S; Cherian B; Arora RR
    Am J Ther; 2010; 17(1):61-7. PubMed ID: 20090431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two amlodipine/ARB combinations for hypertension.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152
    [No Abstract]   [Full Text] [Related]  

  • 24. Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected].
    Pimenta E
    Adv Ther; 2009 Jan; 26(1):1-11. PubMed ID: 19129998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A third amlodipine/ARB combination (Twynsta) for hypertension.
    Med Lett Drugs Ther; 2010 Jan; 52(1329):2-3. PubMed ID: 20208469
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study.
    Ihm SH; Jeon HK; Cha TJ; Hong TJ; Kim SH; Lee NH; Yoon JH; Yoon N; Hwang KK; Jo SH; Youn HJ
    Drug Des Devel Ther; 2016; 10():3817-3826. PubMed ID: 27920497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
    Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
    Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.
    Kang SM; Youn JC; Chae SC; Park CG; Yang JY; Kim MH; Hong TJ; Kim CH; Kim JJ; Shin DG; Jeong JW; Yoon JH; Park SH; Kwon J; Cho SY
    Clin Ther; 2011 Dec; 33(12):1953-63. PubMed ID: 22136978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.
    Sievers P; Uhlmann L; Korkmaz-Icöz S; Fastner C; Bea F; Blessing E; Katus HA; Preusch MR
    Drug Des Devel Ther; 2015; 9():3935-42. PubMed ID: 26251572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.
    Khan BV
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):241-73. PubMed ID: 21893558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the presentation of drug information to pharmacy and therapeutics committees for formulary decisions.
    Sterné SC; Uchida KM; Iteen SA
    Am J Health Syst Pharm; 1996 May; 53(10):1162-4. PubMed ID: 8734677
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.
    Rohatagi S; Lee J; Shenouda M; Haworth S; Bathala MS; Allison M; Rubets I; Heyrman R; Noveck R; Salazar DE
    J Clin Pharmacol; 2008 Nov; 48(11):1309-22. PubMed ID: 18974285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
    Nesbitt SD; Shojaee A; Maa JF; Weir MR
    J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
    Belsey JD
    J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development.
    Friesen P; Caplan AL; Miller JE
    J Clin Pharm Ther; 2020 Apr; 45(2):249-255. PubMed ID: 31657022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
    Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.